SG/CALL/BRISTOL-MYERS SQUIBB/62/0.1/21.06.24 | Delayed Deutsche Boerse AG 03:58:43 04/06/2024 pm IST | ||
| 0.001 EUR | 0.00% |
|
| 6 months | -98.33% | ||
| Current year | -98.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 0.001 | 0.00% |
| 03/24/03 | 0.001 | 0.00% |
| 31/24/31 | 0.001 | 0.00% |
| 30/24/30 | 0.001 | 0.00% |
| 29/24/29 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 04, 2024 at 03:58 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU2KFX |
| ISIN | DE000SU2KFX9 |
| Date issued | 21/11/2023 |
| Strike | 62 $ |
| Maturity | 21/06/2024 (18 Days) |
| Parity | 10 : 1 |
| Emission price | 0.061 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.098 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.019 € |
| Spread % | 95.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.77
USD
Average target price
53.19
USD
Spread / Average Target
+27.35%
- Stock Market
- Warrants
- Warrant
